Collaboration will support growth of emerging modalities by offering custom cGMP solutions to enhance process efficiency and accelerate speed-to-market.
| Collaboration will support growth of emerging modalities by offering custom cGMP solutions to enhance process efficiency and accelerate speed-to-market RADNOR, Pa., June 23, 2022 /PRNewswire/ -- Avantor Performance Materials, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences, advanced technologies and applied materials industries has entered into an agreement with GeminiBio to deliver custom hydrated solutions and cell culture media to the biopharma industry. Custom hydrated solutions and cell culture media are critical components of the bioproduction workflow, especially for emerging modalities such as gene therapy. This collaboration will complement Avantor’s proven ability to serve manufacturing platforms with GeminiBio’s small-to-medium scale offering, enabling customers to utilize custom cGMP products through the full development lifecycle – including early-stage research, scale-up and commercialization. This new capability along with Avantor’s recent acquisitions and site investments, support a growing portfolio of proprietary offerings, demonstrating Avantor’s commitment to supporting customer workflows in both upstream and downstream processing for the biopharma industry. “With the imperative to meet patient needs quickly, our customers require custom solutions to accelerate their bioproduction goals,” said Dr. Ger Brophy, Executive Vice President, Biopharma Production for Avantor. “Customized media is critical in optimizing cell line productivity, and hydrated solutions offer efficiency to biomanufacturers as they optimize their downstream processes. Our collaboration with GeminiBio will drive increases in product yields, helping bring efficiency and speed to our customers as they scale. Together, we can drive science forward to bring therapies to the patients who need them most.” Brian Parker, CEO of GeminiBio stated, “Enabling customers to optimize their upstream and downstream liquid manufacturing workflows by offering custom solutions, built around a strong quality foundation, has been an essential part of GeminiBio’s success. Collaborating with Avantor, who shares our focus on quality, will allow us to expand our ability to address customer needs for both small and large volume process liquids.” About Avantor Business Media Contact Global Media Contact
SOURCE Avantor and Financial News | ||
Company Codes: NYSE:AVTR |
View original content:
